The future biosimilar landscape: the pharmaphorum podcast
For episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet the head of the company’s UK specialty business Kavya Gopal.
There, they spoke about the current state of play in biosimilars and looked ahead to how the landscape will evolve in the future, given the medicines’ consistently rising profile in recent years.
[caption id="attachment_46268" align="alignleft" width="150"]
Kavya Gopal[/caption]
Despite this, it’s only in the last 12 months or so, with the approval of the first cancer and then arthritis biosimilars, that this type of medicine has really started to come to the fore.
As specialty business head for Sandoz UK, not to mention chair of the British Biosimilars Association, Kavya had a wealth of knowledge to share during a discussion that encompassed market developments, policy learnings and pressure points within the regulatory process.
She also talked about market access for biosimilars, variation in biosimilar prescribing and why the medicines matter to cash-strapped healthcare systems, such as the UK’s NHS.
You can listen to episode 3 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the series – in iTunes.
